Cosmax, Inc. Overview
Cosmax, Inc. is the world's largest cosmetics original development manufacturer (ODM) by revenue. It formulates, develops and mass-produces skincare, makeup, hair, body and sun-care products that other companies sell under their own brands. Its client base spans global multinationals such as L'Oréal, a supplier relationship since 2004, and thousands of fast-moving Korean, Chinese, Southeast Asian and US "indie" brands. FY2025 revenue was a record KRW 2,398.8 bn (about USD 1.66 bn), and operating profit was KRW 195.8 bn. Cosmax runs production in Korea, China, the United States, Indonesia, Thailand and, since April 2026, Italy, with stated capacity of about 2.69 bn units a year. The equity story rests on the structural globalisation of K-beauty. Cosmax acts as an outsourced R&D and manufacturing engine behind much of it, and it is widening its model from pure ODM into raw-material design, OBM brand-building services, and co-innovation with L'Oréal.
Company self-description
Cosmax describes itself as a global cosmetics R&D and production (ODM) company that researches, develops and manufactures cosmetics in Korea and overseas. In its DART filing the company states its business as cosmetics, customised cosmetics and other, covering skincare, base makeup, colour makeup, herbal cosmetics, fragrance and hair care (summary of the company profile used in Korean brokerage data). In its 2026 investor materials the company describes supplying more than 4,000 brands in more than 100 countries, with over 90% of sales from ODM contracts (Q2 2026 earnings summary via Quartr). Press materials also cite about 5,000 client companies (Kukinews, Dec 2025; Fortune 2026).
Business model
ODM (core, >90% of sales): Cosmax develops the formula, often proposing finished concepts, textures and claims. It then produces the product at its own plants for the brand owner. Revenue is recognised per unit shipped. Pricing is negotiated product by product and is not publicly disclosed.
OEM: Cosmax manufactures to a formula supplied by the client. This share has declined over time; in the US the ODM share reportedly reached about 80% by 2024 (Dealsite, Sep 2024).
OBM (original brand manufacturing): a newer service layer in which Cosmax supports brand planning as well as R&D and manufacturing. It is active in Thailand since H2 2025 and is being extended group-wide (Dealsite, Nov 2025; Herald Business, 2026).
Ancillary platforms: an export-support platform that helps clients with customs, tariffs and logistics for direct exports; a packaging sourcing platform ("Cosmax Package.com"); and customised-cosmetics/AI personalisation capabilities (TheVC; Newdaily, Mar 2025; Kukinews, May 2025).
Revenue model mix: effectively 100% product revenue (manufactured goods). There is no material subscription, licensing or service revenue line in the sources reviewed.
Value-chain position
Cosmax sits between raw-material and packaging suppliers upstream and brand owners and retailers downstream. It manages about 200 strategic suppliers under an ESG programme (Kukinews, Mar 2025). It is pushing upstream into proprietary raw-material development, which the company says cuts costs by about 30% versus imported materials (Sidae, Mar 2026).
Customer types and end-markets
Global multinationals: L'Oréal (since 2004); Fortune also names Shiseido, Yves Saint Laurent and Lancôme.
Korean indie and mid-size brands: brokers name APR, The Founders, Mediheal, Jung Saem Mool and Clio among recent growth drivers (Hana Securities, Jul 2026; SK Securities, Oct 2026).
Chinese domestic brands: historically Florasis (Huaxizi), Perfect Diary and Ziranzhai (Dealsite, Mar 2022).
Southeast Asian brands: for example Mistine in Thailand (Maeil Business, Jun 2018).
US indie brands: West Coast clients are served through a California sales office (FY2025 results release).
End-markets are prestige and mass skincare, colour cosmetics, sun care, hair and body care, and derma/medical-device cosmetics (via Keminova). Products sell through online, Health & Beauty stores, duty-free, modern and general trade in Southeast Asia, and export channels.
Independent characterisation
Cosmax is best understood as a capacity-plus-formulation-library platform whose growth tracks two things: (i) the number of brands launching products, especially asset-light indie brands that cannot afford in-house R&D, and (ii) the speed at which Korean-designed products are exported. The Korean entity is the profit engine (KRW 154.6 bn of the group's KRW 195.8 bn FY2025 operating profit). Overseas subsidiaries have historically diluted margins, and the US has diluted capital as well. The investment case in 2026 is shifting from "Korea carries the group" to "all regions contribute", following the US unit's first quarterly operating profit in Q2 2026.
Strategy
Stated strategy (paraphrased)
2026 management keyword: adding a premium to customer value through Cosmax's own capabilities (Sidae, Feb 2026).
Stated priorities: - Build overwhelming leadership in strategic categories, especially sun care and base makeup.
-
Expand joint sales across global subsidiaries.
-
Pursue emerging markets in the Middle East, Latin America and Africa.
-
Use the Indonesian and Thai subsidiaries to reach Vietnam and India.
-
Grow with K-indie brands.
-
Consolidate the "world No. 1 ODM" position (FY2025 results release).
Business-model evolution: from order-taking to a "total solution" partner. This combines proprietary raw-material development (about 30% cost saving versus imports), ESG and global-certification consulting, and OBM brand support. R&D is held at 5% or more of sales (Sidae, Mar 2026).
Strategic initiatives, last 24 months
| Initiative | Date | Details | Status |
|---|---|---|---|
| Thailand capacity tripling | Mar 2025 – Sep 2026 | KRW 56 bn / THB 1.5 bn; 36,000 m² plant; up to 230 m units | Scheduled start Sep 2026 |
| Korea capacity expansion | Jan 2025 – end-2025 | +20% (Jan 2025), +30% targeted by end-2025 | Partial verification only |
| US turnaround programme | 2024–2026 | West Coast sales office, ODM share about 80%, fixed-cost reduction, OTC Lab for sunscreen | First quarterly operating profit in Q2 2026 |
| Europe entry (Keminova) | Feb–Apr 2026 | 51% stake; "Made in Italy" positioning; R&D reorganised; "Keminova Academy" planned | Post-merger integration under way (ICE, Jul 2026) |
| L'Oréal co-innovation MOU | Sep 2026 | Global product development, ingredients and actives, sensory signatures and formats | MOU (non-binding) |
| China structure clean-up | 2023–2026 | Buy-out of financial investors; RCPS→CB (2025); early CB redemption and IPO withdrawal (2026) | Completed / in progress |
| Value-up plan | Nov 2025 | 30% shareholder return on standalone net income through 2028; more predictable dividends | In force; FY2025 DPS +43.5% |
| Renewable energy / carbon | May 2026 | PPA with Hanwha Solutions (Q CELLS) for 10.4 GWh a year; about 40% renewable share at Hwaseong and Pyeongtaek; product LCA system | Signed |
| Supplier ESG programme | Mar 2025 | About 200 suppliers: ESG assessments and audits, carbon inventory support, supplier carbon-neutral guideline | Ongoing |
| AI personalisation | 2,025 | Hyper-personalised cosmetics (shampoo first; lip and foundation next) | Early stage |
Medium-term targets and guidance
Financial guidance: Cosmax provides internal guidance (Kyobo, Oct 2026, says Korea and US were tracking above guidance in Q3 2026), but specific numerical medium-term targets were not found in the sources reviewed.
Capital return: 30% shareholder return ratio on standalone net income through 2028 (Value-up Plan).
Earlier target (2024 NDR): a Cosmax China listing in 2026 (Yuanta, Nov 2024). This has been withdrawn (2026).
Products & Services
Cosmax does not publish a client-facing price list or product-by-product sales. The catalog below is organised by category and capability. Named products are client-branded items that Cosmax has been publicly identified as manufacturing. Pricing is not publicly disclosed for any line; ODM pricing is negotiated per SKU.
Skincare (about 64% of Korea Q1 2026 sales, versus 53% in Q1 2025 — Eugene, May 2026)
| Product line | Description / capabilities | Target customer | Notes / flagship evidence |
|---|---|---|---|
| Creams, serums, essences, toners | Core basic skincare with proprietary actives and texture libraries | Indie and MNC brands in Korea, China, US, SEA | SK Securities (Apr 2026) says many leading K-beauty skincare SKUs are Cosmax-made |
| Hydrogel / gel mask packs | High-volume sheet and hydrogel masks; lower margin than creams | Korean indie brands for export | Identified as a Q3–Q4 2025 growth driver; profitability improved in 2026 (Byline; company release, Aug 2026) |
| Sun care (sunscreens, sun serums, sun sticks) | Texture innovation such as "sun serum" formats; inorganic UV filter R&D (zinc oxide, titanium dioxide national R&D project, 2024) | Global brands; US OTC-regulated market | Korea sun-care sales +80% YoY in Q3 2025 (Byline); +50% to about KRW 40 bn in Q2 2025 (Daishin). OTC Lab created for US sunscreen (Dealsite, Sep 2024) |
| Multi-balms / stick formats | Solid stick skincare | Korean brands | "Kahi Multi Balm" cited as a 2021 hit product (Dealsite, Mar 2022) |
| Cleansers | Including a cream-to-oil cleanser composition (2025 patent filing) | All | CosinKorea patent digest (Jul 2025) |
| Derma / medical-device cosmetics | European derma cosmetics, medical-device-classified products | Italian derma brands and pharma companies | Via Keminova (Brescia) from Apr 2026 |
Base makeup
| Product line | Description | Target customer | Notes |
|---|---|---|---|
| Cushion compacts | Signature K-beauty base format | China, Korea, global | Shanghai growth in cushions and foundations, Q2 2026 (Sateconomy, Aug 2026) |
| Foundations, primers | Liquid and cream bases | MNC and indie | Named a strategic category for 2026 alongside sun care (Sidae, Feb 2026) |
Colour cosmetics (about 36% of Korea Q1 2026 sales)
| Product line | Description | Target customer | Notes |
|---|---|---|---|
| Lip (tints, lipsticks) | Broad shade and texture library | Korea, China, US indie | China lip and blusher growth in Q2 2026 |
| Cheek / blusher, eye | Powders, creams | Korean brands such as Jung Saem Mool and Clio | SK Securities (Oct 2026) cites strong colour orders in Q3 2026 |
| US colour (New Jersey) | Colour cosmetics plant from the Nu-World acquisition | US mass and indie | Nu-World made "Hard Candy" and supplied Walmart doors (CNC News, 2017) |
Hair & body care
New focus categories from 2025. The company reported meaningful results in hair and body in Q4 2025 (Hankyung Magazine, Feb 2026). US demand is concentrated in body care and sun care (Quartr Q2 2025 summary). Keminova adds haircare expertise.
Herbal (한방) cosmetics and fragrance
Listed in the company's business description. No revenue split disclosed.
Customised / personalised cosmetics
An AI-driven personalisation platform. The shampoo configurator alone allows 12.6 m combinations, with plans to extend to lipsticks and foundations (Kukinews, May 2025). This is a reported segment line ("customised cosmetics"). Revenue is not disclosed and is believed to be small.
Services and platforms
| Service | Description | Launch / status |
|---|---|---|
| Full-service ODM | Concept, formulation, stability and efficacy testing, regulatory dossiers, production | Core since the 1990s |
| OBM support | Brand planning in addition to R&D and manufacturing | Thailand from H2 2025; expanding group-wide |
| Export support platform | Customs, tariffs and logistics support for clients' direct exports | Operating (TheVC news feed) |
| Cosmax Package.com | Online packaging-sample sourcing for clients and suppliers | Operating (Newdaily, Mar 2025) |
| Raw-material co-development | Proprietary ingredients proposed to clients ("reverse proposals") | Strategic priority 2026 (Sidae, Mar 2026) |
| Global joint sales | Cross-subsidiary account coverage; "Loco Project" low-cost lines in Indonesia/China | 2025–2026 (Cosmax Q4 2025 IR; Eugene) |
Out-of-scope group businesses (not consolidated in 192820)
Health functional foods (Cosmax NBT), pet products (Cosmax Pet, new Jeungpyeong plant), and holding-level beauty-tech ventures (Cosmax BTI). They are noted for context only.
Financial Narrative
Income statement
Sources: FY2021 (Dealsite, Mar 2022); FY2022 (Dealsite, Mar 2023/Mar 2024; DART-based data via ETFShopping); FY2023 (Dealsite, Mar 2024); FY2024–FY2025 (Cosmax FY2025 release, Feb 2026; dividend disclosure, Mar 2026). EBITDA, EPS and controlling NI from Hanwha Investment & Securities (Jan 2025, May 2026). Eugene reports FY2023 EPS of KRW 5,034, a minor discrepancy.
Revenue CAGR FY2021–FY2025: 10.8% (derived). Operating income CAGR: 12.4% (derived).
Quarterly trajectory (most recent 7 quarters)
Sources: Cosmax IR decks (Feb 2025, Nov 2025, Feb 2026); Quartr summaries; Dealsite; Shinhan (Feb 2026); Eugene (May 2026); company release (Aug 2026). Q4 2025 net profit is derived as FY2025 KRW 131.1 bn minus Q1–Q3.
H1 2026: revenue KRW 1,476.9 bn (+22%), operating profit KRW 126.8 bn (+13%), net income KRW 93.8 bn.
Balance sheet
Sources: Valueline (consolidated balance sheet, updated to Q1 2026); Yuanta (Apr 2026); Hanwha (May 2026); Daum Finance BPS of KRW 49,196 × 11.35 m shares.
Borrowing definitions differ materially across brokers. For FY2024, Yuanta's September 2025 report showed KRW 878.5 bn and its April 2026 report KRW 968.5 bn. Kyobo shows KRW 739 bn (FY2024) and KRW 813 bn (FY2025). The differences likely reflect the treatment of lease liabilities and of Cosmax East's RCPS/CB, which were classified as debt.
Latest (31 Mar 2026): total assets KRW 2,516.0 bn; current assets KRW 1,265.3 bn; cash KRW 369.3 bn (Valueline).
Cash flow
Known data points:
-
No share buyback programme was identified.
-
Major disclosed capital projects: new Thailand plant, KRW 56 bn (2025–2026); Pyeongtaek Plant 2 and logistics, KRW 41.5 bn of the 2021 rights issue; automation and lab equipment, KRW 24.0 bn; digital transformation, KRW 16.0 bn (IBK, Apr 2021).
-
Historical: capex jumped from KRW 5.1 bn (2014) to KRW 166.3 bn (2017) in the year of the Nu-World acquisition (Dealsite, Sep 2024).
Ratios
ROE: the trailing ROE was 28.5% as of 14 Oct 2026 (Valueline) and 26.7% on a Q1 2026 basis. A derived FY2025 ROE of about 24% uses controlling NI of KRW 123.1 bn over average controlling equity of about KRW 514 bn; the FY2024 equity is itself estimated from P/B, so treat this as approximate. Debt/equity on the FY2025 controlling-equity basis is about 1.9x (derived, approximate).
Commentary on trends, inflections and drivers
-
FY2021 (expansion): The China online boom (Shanghai online share about 70%) and Korean e-commerce exports lifted operating profit 84%. Revenue was held back by the reversal of 2020 US hand-sanitiser demand.
-
FY2022 (shock): Shanghai lockdowns cut China revenue about 15%. Ethanol and glycerine prices rose 38% and 74% respectively. Operating profit more than halved, and higher finance costs plus US losses produced a consolidated net loss.
-
FY2023 (recovery and Korea inflection): Reopening, inbound tourism and indie-brand exports pushed Korean revenue above KRW 1 tn (+24%). The US moved toward ODM and reduced losses. At the standalone level, the KRW 256.4 bn provision on loans to US subsidiaries exposed the cumulative cost of the US strategy.
-
FY2024 (K-beauty export super-cycle): Revenue +21.9% to KRW 2.17 tn and operating profit +51.6%, driven almost entirely by Korea (+28%) and Southeast Asia. China was flat and the US weak.
-
FY2025 (record year, but uneven): Revenue +10.7% and operating profit +11.6%. Q3 2025 operating profit fell 1.6% because onboarding costs for a surge of new indie clients compressed Korean margins (Korea OP -13% in Q3). Indonesia fell 33% in Q3 amid domestic unrest and cheap imports. Net income rose 48% as non-operating drags eased.
-
H1 2026 (broad-based acceleration): Q2 2026 revenue +27.5% was the first quarter in which every subsidiary grew. Korea topped KRW 500 bn, China grew about 33%, and the US grew 79% and turned profitable. Gross margin held at about 18% despite mix shifts. SG&A rose 32.1% on commissions and bad-debt expense, a watch item.
-
Leverage: Net debt rose from KRW 705 bn to KRW 846 bn in FY2025, and leverage (about 3x EBITDA) remains elevated for a manufacturer. Drivers are the US funding, Cosmax East financing (RCPS→CB→early redemption with a KRW 110 bn intra-group loan), and new plant capex. Management has added KRW 100 bn of short-term bank lines (Sep 2026), so deleveraging depends on H2 2026 cash generation.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Entity revenue (KRW Bn)
| Entity revenue (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cosmax Korea (standalone) | 853.2 | 854.0 | 1,057.6 | 1,357.7 | 1,526.4 |
Cosmax East (China, Shanghai + Guangzhou) | 649.9 | 550.5 | 547.4 | 574.3 | 632.7 |
Cosmax West (USA) | 135.0 | 164.0 | 139.9 | 137.1 | 132.6 |
Cosmax Indonesia | 39.1 | 67.4 | 85.8 | 113.2 | 97.7 |
Cosmax Thailand | 19.9 | — | 25.6 | 43.5 | 73.2 |
Consolidated revenue | 1,591.5 | 1,600.1 | 1,777.5 | 2,166.1 | 2,398.8 |
Results by Segment and Segment Margins & Growth (%)
| Korea standalone | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating profit (KRW Bn) | 77.5 | — | 86.8 | 138.7 | 154.6 |
Operating margin (%) | 9.1 | — | 8.2 | 10.2 | 10.1 |
Revenue growth YoY (%) | 11.0 | 0.1 | 23.8 | 28.4 | 12.4 |
Entity revenue growth (%)
| Entity revenue growth (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Korea | 23.8 | 28.4 | 12.4 |
China (East) | -0.6 | 4.9 | 10.2 |
USA (West) | -14.7 | -2.0 | -3.3 |
Indonesia | 27.3 | 31.9 | -13.7 |
Thailand | — | 70.4 | 68.2 |
Share of entity revenue (%)
| Share of entity revenue (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Korea | 57.4 | 61.0 | 62.0 |
China | 29.7 | 25.8 | 25.7 |
USA | 7.6 | 6.2 | 5.4 |
Indonesia | 4.7 | 5.1 | 4.0 |
Thailand | 1.4 | 2.0 | 3.0 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 1,591.5 | 1,600.1 | 1,777.5 | 2,166.1 | 2,398.8 |
Revenue growth YoY (%) | 15.1 | 0.5 | 11.1 | 21.9 | 10.7 |
Operating income (KRW Bn) | 122.6 | 53.1 | 115.7 | 175.4 | 195.8 |
EBITDA (KRW Bn) | — | — | 175 | 244 | 270 |
Net income, consolidated (KRW Bn) | 34.4 | -16.4 | 37.8 | 88.4 | 131.1 |
Net income to controlling shareholders (KRW Bn, derived from EPS) | — | 20.8 | 57.1 | 85.8 | 123.1 |
EPS basic (KRW) | — | 1,837 | 5,036 | 7,560 | 10,847 |
Dividend per share (KRW) | — | — | — | 2,300 | 3,300 |
Operating margin (%) | 7.7 | 3.3 | 6.5 | 8.1 | 8.2 |
EBITDA margin (%) | — | — | 9.8 | 11.3 | 11.3 |
Net margin, consolidated (%) | 2.2 | -1.0 | 2.1 | 4.1 | 5.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (Quarterly)
| Metric (KRW Bn) | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|
Revenue | 558.0 | 588.6 | 623.6 | 585.6 | 601.0 | 682.0 | 794.9 |
Operating profit | 39.8 | 51.3 | 60.8 | 42.7 | 40.9 | 53.0 | 73.7 |
Net profit (consolidated) | 12.9 | 10.6 | 21.8 | 10.7 | 88.0 | 43.8 | 50.0 |
Gross profit | 108.0 | — | — | — | — | 115.0 | 142.5 |
Operating margin (%) | 7.1 | 8.7 | 9.8 | 7.3 | 6.8 | 7.8 | 9.3 |
Balance Sheet and Balance Sheet (bps)
| Metric (KRW Bn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets | 1,396.4 | 1,557.1 | 1,933.7 | 2,125.4 |
Current assets | 737.2 | 821.6 | 942.5 | 975.0 |
Cash & equivalents | 169.1 | 256.9 | 256.4 | 192.3 |
Total borrowings (Yuanta, Apr 2026 basis) | — | — | 968.5 | 1,044.1 |
Net debt (Hanwha) | — | — | 705 | 846 |
Controlling equity (derived from BPS) | — | — | — | 558 |
Dividends & Capital Returns
| Metric (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Dividends declared, total | 26.1 | 37.4 |
Returns & Leverage Ratios (%) and Valuation Multiples (x)
| Ratio | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROA (%, derived) | 2.6 | 5.1 | 6.5 |
Asset turnover (x, derived) | 1.20 | 1.24 | 1.18 |
Net debt / EBITDA (x, derived) | — | 2.9 | 3.1 |
P/E on average price (x, Hanwha) | — | 29.0 | 20.2 |
P/B on average price (x, Hanwha) | — | 5.3 | 4.5 |
Region revenue (KRW Bn)
| Region revenue (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Korea | 853.2 | 854.0 | 1,057.6 | 1,357.7 | 1,526.4 |
China | 649.9 | 550.5 | 547.4 | 574.3 | 632.7 |
USA | 135.0 | 164.0 | 139.9 | 137.1 | 132.6 |
Indonesia | 39.1 | 67.4 | 85.8 | 113.2 | 97.7 |
Thailand | 19.9 | — | 25.6 | 43.5 | 73.2 |
Region growth (%)
| Region growth (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Korea | 23.8 | 28.4 | 12.4 |
China | -0.6 | 4.9 | 10.2 |
USA | -14.7 | -2.0 | -3.3 |
Indonesia | 27.3 | 31.9 | -13.7 |
Thailand | — | 70.4 | 68.2 |
Group Entities
| Entity (KRW Bn) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Korea | 362.8 | 420.5 | 383.5 | 359.7 | 423.2 | 518.4 |
China | 162.7 | 148.6 | 140.0 | 181.4 | 194.7 | 197.4 |
USA | 28.7 | 30.0 | 36.9 | 37.0 | 42.0 | 53.8 |
Indonesia | 29.6 | 20.9 | 21.5 | 25.7 | 22.7 | 28.9 |
Thailand | 23.9 | 23.1 | 15.2 | 11.1 | 24.3 | 24.9 |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Last price | KRW 282,000 | 14 Oct 2026 (Valueline) |
Market capitalisation | about KRW 3,229 bn | 14 Oct 2026 |
52-week high / low | KRW 306,500 / KRW 141,000 (low on 26 Jun 2026) | Google Finance; Daum Finance |
Return 1M / 3M / 6M / 1Y | +1.5% / +72.7% / +40.2% / +17.3% | 7 Sep 2026 (WiseReport) |
Average daily trading value (60D) | about KRW 18 bn | May 2026 (Yuanta, Kyobo) |
Valuation Multiples (x) and Per-Share Data
| Valuation metric | FY2024 | FY2025 |
|---|---|---|
P/E (x) | 29.0 | 20.2 |
P/B (x) | 5.3 | 4.5 |
Dividend per share (KRW) | 2,300 | 3,300 |
Valuation Multiples
| Multiple | Cosmax | Kolmar Korea |
|---|---|---|
Trailing P/E (x) | 17.5 | 18.0 |
Forward P/E (x) | about 23.4 on Hanwha's May 2026 FY2026E EPS of KRW 12,048 (now likely stale given upgrades) | 18.0 (fPER, Butler) |
P/B (x) | 5.0 | 3.3 |
EV/EBITDA FY2025 (x, derived) | about 15.1 (EV ≈ KRW 4,075 bn = mkt cap + FY2025 net debt; excludes minorities) | — |
EV/Sales FY2025 (x, derived) | about 1.7 | — |
Dividend yield (%) | about 1.2 (KRW 3,300 / KRW 282,000) | 0.6 |
ROE (%) | 28.5 (TTM) | — |
Analyst Ratings & Targets
| Broker | Rating | Target price (KRW) | Q3 2026E revenue (KRW Bn) | Q3 2026E OP (KRW Bn) | Date |
|---|---|---|---|---|---|
Kyobo Securities | Buy | 410,000 | 820.0 | 78.2 | 7 Oct 2026 |
Hana Securities | Buy | 380,000 | 823.8 | 79.0 | 7 Oct 2026 |
SK Securities | Buy | 370,000 | 823.8 | 75.6 | 7 Oct 2026 |
Yuanta Securities | Buy | 363,000 | 815.0 | 83.0 | 7 Oct 2026 |
Market consensus (Q3 2026 OP) | — | — | — | 67.7 | Oct 2026 |
Analyst Conclusions
Management guidance
No public numerical guidance was identified. Management's H2 2026 messaging centres on continued skincare strength, global K-beauty demand and new-client ramp-ups, with the US entering a "full turnaround phase". Brokers report Korea and the US tracking above internal guidance in Q3 2026.
Consensus expectations
-
Q3 2026 operating-profit consensus is KRW 67.7 bn. Leading brokers' October 2026 estimates of KRW 75.6–83.0 bn imply a further upward revision cycle.
-
Revenue growth expectations for Q3 2026 are about +39–41% YoY. Brokers expect Korea +45–47%, US about +70%, China +21–35%, Indonesia about +30% and Thailand +20–25%.
Bull case
-
Operating leverage is only starting. With utilisation at 40–60% outside Korea, every overseas unit now growing double digits, and the US profitable, consolidated margins can move above the FY2025 level of 8.2%. Q3 2026 broker estimates imply roughly 9.2–10.2%.
-
Structural share gain in a structural market. Korean cosmetics exports hit a record USD 11.4 bn in 2025. Cosmax's Korean revenue has nearly doubled since 2022 (KRW 854 bn to KRW 1,526 bn), and the L'Oréal MOU signals MNC outsourcing of innovation to Cosmax.
-
Value capture and capital return. The Cosmax East IPO withdrawal removes double-listing risk. The 30% return policy and high-dividend status support ownership by domestic income investors.
Bear case
-
The US history is the base rate. Ten years of losses, full capital impairment and repeated provisions argue that one profitable quarter (Q2 2026) is not proof of sustainability. Fresh guarantees (USD 50 m) show the unit still needs parent support.
-
Balance-sheet strain. Net debt of about KRW 846 bn (about 3.1x EBITDA) is rising with the Cosmax East redemption loan, new short-term borrowing, Thai capex and the Keminova purchase. Net margins have historically been eroded by interest and FX.
-
Sentiment risk after a doubling. The stock more than doubled from June 2026. Results misses produced drawdowns of about 27% (Aug 2025) and about 12.7% (Nov 2025). Indie-brand demand and colour exports are cyclical.
Catalysts and monitorables (next 12 months)
Q3 2026 results (about 10 Nov 2026): beat versus the KRW 67.7 bn consensus; Korea operating profit above KRW 60 bn; size of the CB-redemption one-off (about KRW 10 bn per SK).
US: sustainability of quarterly operating profit through Q3 and Q4 2026.
Thailand: ramp-up and utilisation of the new Bang Phli plant.
Keminova: first consolidated contribution and new EU client wins.
L'Oréal: conversion of the MOU into projects.
Capital structure: net-debt trajectory and refinancing of short-term lines.
FY2026 dividend: declaration (Feb–Mar 2027) under the 30% return policy.
Governance: succession signals at Cosmax BTI.
Margins: SG&A and bad-debt trends (Q2 2026 SG&A +32%).
Analyst verdict
Cosmax enters late 2026 at the strongest operating point in its history. Revenue has compounded at about 11% a year since FY2021, operating profit reached a record KRW 195.8 bn in FY2025, and H1 2026 showed something the company had not delivered in a decade: simultaneous growth and profitability across Korea, China, the US and Southeast Asia. The core asset, the Korean entity with roughly KRW 1.5 tn of revenue and about 10% margins, is a genuine global franchise. It is positioned as the outsourced R&D and production backbone of the K-beauty export boom and is now formally aligned with L'Oréal on innovation.
The dossier also documents why this company has historically traded at a discount to its operating story. Capital allocation abroad has been poor. The US cost hundreds of billions of won in provisions, and the China structure required two rounds of financial-investor buy-outs. Consolidated net margins have rarely exceeded 5%, and leverage of about 3x EBITDA is high for a contract manufacturer. Disclosure in English is thin, and several basic data points, including executive pay, cash-flow detail and ESG ratings, are hard to verify.
The investment question for the next twelve months is therefore less about demand, which brokers and the order book suggest is robust, than about conversion. Cosmax needs to turn record revenue into durable consolidated margins, free cash flow and deleveraging, while integrating Keminova and filling new Thai capacity without repeating the US pattern. At about 17.5x trailing earnings and about 15x EV/EBITDA, the market already prices substantial improvement after a doubling from the June 2026 low. Our synthesis: fundamentally strong and improving, with execution and balance-sheet risk that warrants position sizing discipline. The Q3 2026 print, US profitability through year-end, and the net-debt trend are the decisive tests of whether the 2026 inflection is structural rather than cyclical.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / background | Source |
|---|---|---|---|
Lee Kyung-soo | Founder; Chairman, Cosmax Group | Founded the company in 1992. Silver Tower Order of Industrial Service Merit (2015). | Herald Business (2026) |
Choi Kyoung (Choi Kyung) | Vice Chairman and Representative Director (CEO), Cosmax, Inc. | Signed the L'Oréal MOU (Sep 2026). Leads the supplier ESG programme. | L'Oréal (Sep 2026); Kukinews (Mar 2025); WEPs registry |
Lee Byung-man (b. 1978) | Vice Chairman (promoted for 2026); co-representative director of Cosmax, Inc.; leads the group ODM business (R&D, production, quality, global clients) | Eldest son of the founder. Became largest shareholder of Cosmax BTI in May 2026 per Fortune | Creatrip (2026); TheVC; Fortune (2026) |
Lee Byung-ju (b. 1979) | Vice Chairman and CEO, Cosmax BTI (holding) | Younger son. Oversees group strategy, new businesses (personalisation, beauty tech), M&A including Keminova | Creatrip; GlobeNewswire (Feb 2026) |
Huh Min-ho | Senior Vice Chairman, Cosmax Group | Joined for the 2026 reshuffle to lead growth strategy and management infrastructure; retail background | Creatrip (2026) |
Seo Seong-seok (Sung Suk Suh) | Co-founder; Chairwoman, Cosmax BTI | Holds about 21.62% (of BTI, per Creatrip) | Fortune; Creatrip |
Kang Min-gu | CEO, Cosmax Thailand | Led the Bang Phli expansion | Korea Times (Apr 2025) |
Major Shareholders
| Holder | Stake (%) | Date / source |
|---|---|---|
Cosmax BTI and related parties (10–11 persons) | 27.51 | May 2026 (Kyobo, Hanwha) |
National Pension Service | 11.22 | May 2026 (Kyobo) |
GIC Private Limited (and 1 other) | 6.3 | May 2026 (Hanwha) |
Employee Stock Ownership Association (and 1 other) | 1.8 | Jan 2025 (Hanwha) |
Foreign ownership, total | 35.16–39.4 | Sep 2026 (WiseReport) / May 2026 |
Competitive Landscape
Key Competitors
| Competitor | HQ | Segment overlap | Positioning vs Cosmax | Revenue (latest verified) |
|---|---|---|---|---|
Kolmar Korea (161890) | Korea | Skincare / sun-care ODM; also pharma (HK inno.N), packaging, food | Main domestic rival; more diversified (cosmetics about 61% of revenue); strong in sun care | FY2025: KRW 2,722.4 bn revenue, KRW 239.6 bn OP, KRW 168.3 bn net (consolidated, all segments) |
Cosmecca Korea | Korea | Colour and skincare ODM | Mid-tier Korean ODM | — |
C&C International | Korea | Lip / colour ODM | Colour specialist | — |
Intercos | Italy | Global makeup ODM | Leading Western makeup ODM; direct rival in Europe and US colour | — |
Fareva (incl. makeup units) | France | Contract manufacturing for beauty and pharma | Large private European CMO | Not disclosed (private) |
Nihon Kolmar | Japan | Cosmetics OEM/ODM | Japanese market | — |
Toyo Beauty | Japan | Cosmetics OEM/ODM | Japanese market | — |
Chinese domestic ODMs | China | Skincare and colour ODM for C-beauty | Price competition for Cosmax East | — |
US contract manufacturers | USA | Skincare, OTC sun, colour | Incumbents in US indie and mass | — |
In-house manufacturing (Amorepacific, LG H&H, large MNCs) | Various | Captive production | Substitutes for outsourcing | — |
Peer Comparison FY2025
| Metric | Cosmax | Kolmar Korea |
|---|---|---|
Revenue (KRW Bn) | 2,398.8 | 2,722.4 |
Revenue growth (%) | 10.7 | 11.0 |
Operating margin (%) | 8.2 | 8.8 |
Net income (KRW Bn) | 131.1 | 168.3 |
R&D intensity (%) | 5.54 | about 6.5–7 (2023) |
Market cap (KRW Bn, Oct 2026) | about 3,229 | about 3,335 |



